MASLD in Pediatric Patients: Epidemiology and Management

Metabolic dysfunction–associated steatotic liver disease (MASLD) has become the leading cause of chronic liver disease in pediatric populations, reflecting the concerning global rise in obesity, insulin resistance, and related metabolic disorders. Once considered a disease of adulthood, MASLD is increasingly recognized in children, adolescents, and young adults. Early-onset MASLD often follows a more aggressive course than adult-onset disease, with faster progression to fibrosis, cirrhosis, and associated extrahepatic complications, including type 2 diabetes mellitus, dyslipidaemia, hypertension, and obstructive sleep apnoea. The consequences go beyond liver health, affecting long-term cardiometabolic outcomes, mental health, and overall quality of life.This Research Topic aims to gather high-quality original research, systematic and narrative reviews, and clinical perspectives on the epidemiology, pathophysiology, diagnosis, and management of MASLD in pediatric and young adult populations. By bringing together multidisciplinary expertise from hepatology, endocrinology, pediatrics, nutrition, mental health, and public health, the collection aims to provide an up-to-date, comprehensive overview of this complex and multifaceted disease.We especially welcome contributions on:1. Epidemiology and risk factors in pediatric and young adult groups, including genetic susceptibility, lifestyle influences, socio-economic determinants, and the developmental origins of health and disease.2. Natural history and disease progression, with a focus on predictors of fibrosis, transitional care, and clinical challenges faced when moving from pediatric to adult healthcare services.3. Innovations in diagnosis, such as non-invasive imaging techniques, serum biomarkers, and artificial intelligence–based risk stratification tools validated in younger populations.4. Management strategies, including lifestyle modifications, nutritional interventions, emerging pharmacological therapies tailored for younger patients, and initiatives promoting prevention for MASLD and metabolic syndrome within schools, communities, and policy frameworks, as well as evaluation of implementation challenges.5. Integrated care models linking pediatric hepatology, endocrinology, primary care, and mental health support, with active involvement of patients, families, and caregivers.6. Psychosocial and mental health aspects of MASLD, with a focus on their impact on disease management and quality of life.Given the often silent presentation of MASLD and its strong link with cardiometabolic health, early detection and intervention are vital to prevent irreversible liver damage and reduce future health burdens. Through this collection, we aim to encourage scientific debate, share innovative approaches, and promote evidence-based strategies that can be adopted across diverse healthcare systems.By encouraging collaboration among clinicians, researchers, and public health professionals, this Research Topic aims to enhance understanding, inform clinical practice, and improve long-term outcomes for children, adolescents, and young adults living with MASLD. Topic editors: Anna Di Sessa, Salvatore Corrao Source: https://www.frontiersin.org/research-topics/73754/masld-in-pediatric-patients-epidemiology-and-management